Nyxoah SA Ordinary Shares (NYXH) Stock Price

NYXHStock

$1.11−80.28%52W

Market Cap$113.04M

P/E—

PEG Ratio—

Div yield—

Beta0.77

NYXH Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-73.74%

Price vs S&P 500 (4W)-21.87%

VGM Score54.66

Book Value / Share (Quarterly)$0.93

P/TBV (Annual)4.94x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)48.11%

Cash Flow / Share (Quarterly)$-0.83

Price vs S&P 500 (YTD)-86.09%

Gross Margin (TTM)60.16%

Net Profit Margin (TTM)-367.79%

EPS (TTM)$-2.43

10-Day Avg Trading Volume0.18M

EPS Excl Extra (TTM)$-2.43

Revenue Growth (5Y)170.65%

EPS (Annual)$-2.65

ROI (Annual)-98.77%

Gross Margin (Annual)63.13%

Net Profit Margin (5Y Avg)-1491.46%

Cash / Share (Quarterly)$1.10

Revenue Growth QoQ (YoY)472.76%

ROA (Last FY)-76.04%

Revenue Growth TTM (YoY)299.17%

EBITD / Share (TTM)$-2.00

ROE (5Y Avg)-64.85%

Operating Margin (TTM)-310.76%

Cash Flow / Share (Annual)$-1.82

P/B Ratio1.31x

P/B Ratio (Quarterly)1.82x

Net Income / Employee (Annual)$-656,668

EV / Revenue (TTM)5.33x

Net Interest Coverage (TTM)-68.54x

ROA (TTM)-80.31%

EPS Incl Extra (Annual)$-2.65

Current Ratio (Annual)1.25x

Quick Ratio (Quarterly)2.31x

3-Month Avg Trading Volume0.21M

52-Week Price Return-80.28%

Revenue / Employee (TTM)$143,569

Tangible BV / Share (Quarterly)$0.39

P/S Ratio (Annual)10.90x

Asset Turnover (Annual)0.08x

52-Week High$5.83

Operating Margin (5Y Avg)-1461.02%

EPS Excl Extra (Annual)$-2.65

CapEx CAGR (5Y)7.45%

Tangible BV CAGR (5Y)77.76%

26-Week Price Return-63.83%

Quick Ratio (Annual)1.16x

13-Week Price Return-27.22%

Total Debt / Equity (Annual)0.86x

Current Ratio (Quarterly)2.38x

Enterprise Value$117.91M

Revenue / Share Growth (5Y)143.04%

Asset Turnover (TTM)0.15x

Book Value / Share Growth (5Y)-23.64%

Revenue / Employee (Annual)$73,075

Inventory Turnover (Annual)0.79x

Pretax Margin (Annual)-888.98%

Cash / Share (Annual)$1.25

3-Month Return Std Dev69.40%

Gross Margin (5Y Avg)63.57%

Net Income / Employee (TTM)$-699,772

ROE (Last FY)-183.36%

Net Interest Coverage (Annual)-13.75x

EPS Basic Excl Extra (Annual)$-2.65

Receivables Turnover (TTM)4.02x

Total Debt / Equity (Quarterly)0.72x

EPS Incl Extra (TTM)$-2.43

Receivables Turnover (Annual)2.21x

ROI (TTM)-101.49%

P/S Ratio (TTM)5.54x

Pretax Margin (5Y Avg)-1406.15%

Revenue / Share (Annual)$0.30

Tangible BV / Share (Annual)$1.89

Price vs S&P 500 (52W)-95.81%

Year-to-Date Return-75.52%

5-Day Price Return-14.24%

EPS Normalized (Annual)$-2.65

ROA (5Y Avg)-37.16%

Net Profit Margin (Annual)-899.05%

Month-to-Date Return-18.17%

Cash Flow / Share (TTM)$-1.79

EBITD / Share (Annual)$-2.33

Operating Margin (Annual)-833.18%

LT Debt / Equity (Annual)0.36x

ROI (5Y Avg)-44.45%

LT Debt / Equity (Quarterly)0.42x

EPS Basic Excl Extra (TTM)$-2.43

P/TBV (Quarterly)4.31x

P/B Ratio (Annual)3.58x

Inventory Turnover (TTM)1.91x

Pretax Margin (TTM)-358.84%

Book Value / Share (Annual)$1.28

Price vs S&P 500 (13W)-29.91%

Beta0.77x

Revenue / Share (TTM)$0.39

ROE (TTM)-175.29%

52-Week Low$1.12

vGradeC

gGradeA

mGradeF

vgmGradeC

NYXH Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	-$0.45	-$0.65	-42.86%(-$0.19)
Q4 2025	Mar 19, 2026	-$0.62	-$0.66	-6.62%(-$0.04)
Q3 2025	Nov 13, 2025	-$0.63	-$0.71	-11.78%(-$0.08)
Q2 2025	Aug 18, 2025	-$0.64	-$0.62	+3.23%(+$0.02)

NYXH Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.07

4.08

Industry Peers — Surgical & Medical Instruments(142)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth (5Y)	Gross Margin (TTM)	Operating Margin (TTM)	Price
NYXHNyxoah SA Ordinary Shares	C	A	F	5.5x	170.7%	60.2%	-310.8%	$1.11
SYKStryker Corporation	C	B	C	4.4x	11.8%	65.3%	21.3%	$294.66
MMM3M Company	C	D	B	3.4x	-5.0%	39.4%	18.4%	$164.75
BSXBoston Scientific Corp.	C	B	C	3.1x	15.2%	69.5%	19.8%	$44.39
BDXBecton, Dickinson and Co.	B	D	A	2.5x	6.3%	46.7%	9.6%	$191.75
MDLNMedline Inc. Class A common stock	C	D	C	1.6x	—	26.2%	6.0%	$35.96
RMDResMed Inc.	C	C	B	5.9x	12.1%	61.1%	33.4%	$238.97
DXCMDexCom, Inc.	C	B	B	6.5x	19.3%	64.3%	22.9%	$86.04
WSTWest Pharmaceutical Services, Inc.	D	C	A	8.5x	7.4%	36.8%	20.4%	$384.02
SOLVSolventum Corporation	C	C	B	1.8x	—	54.8%	23.9%	$85.81
BAXBaxter International Inc.	B	D	B	1.1x	-0.8%	30.7%	-2.3%	$25.28
PENPenumbra, Inc.	F	C	B	8.4x	20.2%	67.8%	12.4%	$320.86
GMEDGLOBUS MEDICAL INC	B	B	B	3.3x	30.1%	68.5%	20.6%	$76.71
PODDInsulet Corporation	C	A	C	3.2x	24.5%	71.1%	16.9%	$141.10
GKOSGlaukos Corporation	F	A	B	15.9x	17.7%	79.1%	-31.6%	$164.84
TFXTeleflex Incorporated	B	F	B	2.1x	-4.7%	53.8%	-11.7%	$130.43
HAEHaemonetics Corporation	C	C	A	4.0x	8.9%	59.1%	11.9%	$118.28
MMSIMerit Medical Systems Inc	C	B	B	3.4x	9.5%	49.5%	12.8%	$89.20
STVNStevanato Group S.p.A.	D	C	C	3.7x	12.4%	29.9%	16.4%	$18.90
MMEDMiniMed Group, Inc. Common Stock	—	—	B	—	—	—	—	$17.49
HTFLHeartflow, Inc. Common Stock	F	A	A	19.8x	—	80.1%	-40.8%	$48.29
ICUIICU Medical Inc	C	D	B	1.9x	11.9%	39.1%	3.5%	$162.99
IRTCiRhythm Holdings, Inc. Common Stock	D	B	C	4.3x	23.0%	71.5%	-3.0%	$108.66
PLSEPulse Biosciences, Inc Common Stock (DE)	F	—	A	2725.9x	—	0.3%	-7007.8%	$44.43
ATRCAtriCure, Inc.	D	B	A	5.0x	20.9%	76.3%	2.3%	$56.07
UFPTUFP Technologies Inc	C	B	A	3.6x	27.4%	28.5%	15.3%	$291.67
INSPInspire Medical Systems, Inc.	B	B	B	2.2x	51.2%	86.1%	6.0%	$68.79
LMATLeMaitre Vascular, Inc.	C	B	C	7.0x	14.0%	72.9%	29.5%	$80.82
NVCRNovoCure Limited Ordinary Shares	D	C	C	2.3x	5.8%	76.1%	-22.1%	$14.07
KMTSKestra Medical Technologies, Ltd. Common Stock	F	A	B	15.2x	—	53.9%	-140.4%	$27.24
ATECAlphatec Holdings, Inc.	D	B	C	2.0x	39.5%	70.8%	-7.5%	$10.46
DRTSAlpha Tau Medical Ltd. Ordinary Shares	—	—	B	—	—	—	—	$12.29
TNDMTandem Diabetes Care, Inc.	D	C	C	1.1x	15.3%	56.0%	-4.4%	$16.24
IRMDiRadimed Corporation	D	B	B	13.1x	21.4%	75.9%	31.9%	$88.27
AORTArtivion, Inc.	C	C	C	2.3x	11.8%	64.4%	2.9%	$21.78
IARTIntegra LifeSciences Holdings	B	F	C	0.6x	3.6%	57.2%	4.0%	$13.21
PRCTPROCEPT BioRobotics Corporation Common Stock	C	A	D	3.0x	109.0%	64.2%	-33.9%	$17.57
BVSBioventus Inc. Class A Common Stock	B	C	A	1.9x	12.1%	68.7%	10.0%	$13.30
BBNXBeta Bionics, Inc. Common Stock	D	A	C	7.4x	—	58.3%	-69.8%	$16.35
SIBNSI-BONE, Inc. Common Stock	D	B	B	4.1x	22.3%	79.5%	-8.3%	$19.68
SGPSpyGlass Pharma, Inc. Common Stock	—	—	B	—	—	—	—	$24.00
MDXGMiMedx Group, Inc	C	D	C	1.8x	11.0%	78.8%	2.5%	$4.43
KIDSOrthoPediatrics Corp. Common Stock	C	B	B	2.3x	27.2%	73.7%	-11.9%	$21.95
TCMDTactile Systems Technology, Inc.	B	B	B	1.5x	12.0%	51.9%	10.0%	$22.52
SSIISS Innovations International Inc. Common Stock	F	A	D	9.7x	—	47.6%	-16.2%	$2.53
DCTHDelcath Systems Inc	D	C	B	5.1x	120.1%	87.0%	-1.9%	$14.08
ANGOAngioDynamics, Inc.	C	D	C	1.5x	1.9%	55.6%	-11.2%	$11.24
BWAYBrainsway Ltd. American Depositary Shares	D	B	B	9.5x	12.2%	74.9%	5.8%	$11.44
SGHTSight Sciences, Inc. Common Stock	D	B	A	5.5x	22.9%	88.4%	-33.4%	$8.28
CERSCerus Corp	D	C	C	1.8x	15.4%	57.2%	-0.7%	$2.18
NPCENeuropace, Inc. Common Stock	D	C	C	4.3x	19.4%	79.6%	-15.3%	$12.24

About Nyxoah SA Ordinary Shares

Nyxoah SA develops and commercializes the Genio system, a CE-Mark validated bilateral neurostimulation therapy for moderate to severe Obstructive Sleep Apnea (OSA). The company addresses a substantial patient population, as OSA is associated with increased mortality risk and serious comorbidities including cardiovascular disease, depression, and stroke. Genio represents a novel treatment approach in a significant market opportunity for sleep-disordered breathing.